Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting

A promising strategy in cancer immunotherapy is the employment of a bispecific agent that can bind with both tumor markers and immunocytes for recruitment of lymphocytes to tumor sites and enhancement of anticancer immune reactions. Mucin1 (MUC1) is a tumor marker overexpressed in almost all adenoca...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhaoyi, Hu, Yan, An, Yacong, Duan, Jinhong, Li, Xundou, Yang, Xian-Da
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385031/
https://www.ncbi.nlm.nih.gov/pubmed/30699986
http://dx.doi.org/10.3390/molecules24030478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385031/
https://www.ncbi.nlm.nih.gov/pubmed/30699986
http://dx.doi.org/10.3390/molecules24030478

Ejemplares similares